Midge Ure has needed to cancel his upcoming tour attributable to a well being situation needing “pressing” therapy.The Ultravox singer will carry out in August however take time without work from September, with exhibits dropped in Australia and throughout Europe.Ure, 71, wrote on social media: “Throughout a latest routine check-up, docs found a well being situation that requires pressing therapy and a interval of restoration.”The Scottish star, from Cambuslang close to Glasgow, organised Reside Help alongside Sir Bob Geldof and had Eighties chart hits with Ultravox and Visage.Ure stated the cancelled gigs could be rescheduled for a future date.He wrote: “I do know lots of you journey nice distances, usually throughout borders to attend the exhibits, and I by no means take that help with no consideration. “I am actually sorry for any inconvenience or disruption this causes to your plans.”I stay totally dedicated to performing all exhibits at the moment scheduled for this month and I am trying ahead to being on the market with you for so long as I am in a position.”Ure stated he was aiming to be again as quickly as potential and {that a} 2026 UK tour – titled A Man of Two Worlds – could be going forward as deliberate. A 2013 ballot voted Ultravox’s 1981 single Vienna as the best quantity two hit in historical past, after it was stored off the highest spot by novelty monitor Shaddup You Face by Joe Dolce.
Trending
- ‘A duty to intervene’: the former UK government lawyer at centre of pro-Palestine protests | Protest
- Gold futures jump to record high after US tariffs on cast bars | Gold
- Qualcomm just hinted at a full-blown server invasion with new CPUs and racks, and nobody’s ready for it
- Social media accounts of Palestinians desperate for funds are being flagged as spam | Technology
- Fantasy football: here come TV’s Welcome to Wrexham rip-offs | US television
- Banker Bao Fan reportedly released from Chinese detention after two years | China
- How to maximize case management to empower modern litigation
- This Startup Aims To Grow New Mini-Organs In Patients